Non-infectious Anterior Uveitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Non-infectious anterior uveitis, the most prevalent form of uveitis, exhibits a variable clinical course predominantly of idiopathic origin. This type of uveitis can be linked to a diverse range of systemic and ocular disorders. HLA B27 positivity emerges as the most common association, notably prevalent in most acute unilateral cases. While the pathogenesis of non-infectious anterior uveitis remains poorly understood, it is likely multifactorial, with diverse genetic and immune response alterations observed across different subtypes. Complications, including cataracts, band keratopathy, glaucoma, macular edema, and hypotony, pose risks of visual impairment. The primary approach to treatment involves the use of topical or local steroids, although in cases that prove resistant or severe, steroid-sparing therapies are considered.
Thelansis’s “Non-infectious Anterior Uveitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-infectious Anterior Uveitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Non-infectious Anterior Uveitis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Non-infectious Anterior Uveitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment